Wednesday, Apr. 23, 2014

Investor News

Halozyme Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH20
April 04, 2014 - Comments Off

SAN DIEGO, April 4, 2014 /PRNewswire/ – Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that as a result of a recommendation received yesterday [...]

Featured Articles

Staying Competitive in the Workforce With Continuing Education for Employees
April 04, 2014 - Comments Off

In today’s fast-paced and ever-evolving business world, employees have to be constantly learning and growing if they want to [...]

Follow Us